About DBV Technologies S.A.
https://www.dbv-technologies.comDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
CEO
Daniel Tassé
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-11-29 | Reverse | 1:5 |
| 2024-06-07 | Reverse | 1:2 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JANUS HENDERSON INVESTORS US LLC
Shares:2.51M
Value:$43.48M
BAKER BROS. ADVISORS LP
Shares:1.46M
Value:$25.34M
VIVO CAPITAL, LLC
Shares:1.05M
Value:$18.29M
Summary
Showing Top 3 of 44
About DBV Technologies S.A.
https://www.dbv-technologies.comDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $32.61M ▼ | $-33.02M ▲ | 0% | $-1.6 ▲ | $-31.5M ▲ |
| Q2-2025 | $0 | $38.49M ▲ | $-42.4M ▼ | 0% | $-1.7 ▼ | $-38.49M ▼ |
| Q1-2025 | $0 ▼ | $22.91M ▼ | $-27.1M ▼ | 0% ▲ | $-1.3 ▼ | $-22.91M ▲ |
| Q4-2024 | $511K ▼ | $24.37M ▼ | $-23.02M ▲ | -4.5K% ▼ | $-1.2 ▲ | $-23.22M ▲ |
| Q3-2024 | $1.07M | $31.4M | $-30.44M | -2.84K% | $-1.6 | $-28.64M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $69.84M ▼ | $110.5M ▼ | $57.64M ▲ | $52.85M ▼ |
| Q2-2025 | $103.21M ▲ | $143.43M ▲ | $57.2M ▲ | $86.22M ▲ |
| Q1-2025 | $12.96M ▼ | $50.56M ▼ | $47.69M ▲ | $2.87M ▼ |
| Q4-2024 | $32.46M ▼ | $65.66M ▼ | $38.27M ▼ | $27.39M ▼ |
| Q3-2024 | $46.44M | $93.06M | $39.02M | $54.03M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-33.16M ▲ | $-32.44M ▲ | $-241K ▼ | $130K ▼ | $-33.37M ▼ | $-32.55M ▲ |
| Q2-2025 | $-41.88M ▼ | $-33.91M ▼ | $-38K ▲ | $116.95M ▲ | $90.25M ▲ | $-33.94M ▼ |
| Q1-2025 | $0 ▲ | $-19.67M ▼ | $-375K ▼ | $45K ▼ | $-19.49M ▼ | $-19.67M ▼ |
| Q4-2024 | $-23.02M ▲ | $-12.25M ▲ | $793K ▲ | $675K ▲ | $-13.98M ▲ | $-12.13M ▲ |
| Q3-2024 | $-30.44M | $-22.46M | $-109K | $7K | $-19.77M | $-22.85M |
CEO
Daniel Tassé
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-11-29 | Reverse | 1:5 |
| 2024-06-07 | Reverse | 1:2 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Cantor Fitzgerald
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
JANUS HENDERSON INVESTORS US LLC
Shares:2.51M
Value:$43.48M
BAKER BROS. ADVISORS LP
Shares:1.46M
Value:$25.34M
VIVO CAPITAL, LLC
Shares:1.05M
Value:$18.29M
Summary
Showing Top 3 of 44